A comparison of the effects of two putative 5-hydroxytryptamine renal prodrugs in normal man

1. The effects of 1 h intravenous infusions of equimolar amounts of two putative 5-hydroxytryptamine (5-HT) renal prodrugs, 5-hydroxy-L-tryptophan (5-HTP, 10 micrograms kg-1 min-1) and gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP, 16.6 micrograms kg-1 min-1) were examined in five healthy male volunteers in a randomised, placebo-controlled, cross-over study. 2. Both compounds increased urinary excretion of 5-HT and there was greater extra-renal formation of 5-HT following 5-HTP administration than after glu-5-HTP. 3. Glu-5-HTP was significantly antinatriuretic. 5-HTP reduced mean urinary sodium excretion but this effect was not statistically significant. 4. 5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone. There was no increase in plasma renin activity with either compound. 5. There were no significant changes in pulse rate or blood pressure. Two subjects complained of nausea at the end of 5-HTP infusion but none had any adverse reactions with glu-5-HTP. 6. The results of this study suggest that both prodrugs generate 5-HT in man and that glu-5-HTP is antinatriuretic. The glutamyl derivative may have greater renal specificity than 5-HTP and, as a result, causes less systemic side effects.

Dopamine and the kidney: ten years on

Ten years ago the Editorial Board of Clinical Science invited me to write an Editorial Review on dopamine and the kidney. The result was published in 1982 in Volume 62 [1]. It was my hope that it would serve to stimulate other investigators to take up this area of renal physiology and pharmacology and to help to solve some of the problems left unanswered at that time. Since 1982 much has happened: there have been major successes, such as the delineation of the renal and adrenal dopamine receptors, and some relative failures, such as the lack of development of clinically useful peripheral dopamine agonists for use in hypertension and congestive cardiac failure. Nevertheless, continuous progress has been made and it is my task in this Review to try to describe this general advance while not omitting remaining areas of uncertainty.

The areas which I will undertake to describe are:

1. The renal receptors for dopamine. 2. The source of dopamine in the urine and its formation in the kidney. 3. The actions of dopamine upon the kidney. 4. The interaction of renal dopamine with other substances. 5. Dopamine formation in hypertensive and oedematous states. 6. The search for specific peripheral dopaminergic agonists of therapeutic utility. 7. Final conclusions and unanswered questions.

Urinary dopamine response to angiotensin II is not abnormal in type 1 (insulin-dependent) diabetes mellitus

To examine the interaction between angiotensin II (ANGII) and dopamine in type 1 diabetes mellitus, urinary dopamine excretion was examined during ANGII infusion in 15 diabetic patients and 10 control subjects after pretreatment with lithium 750 mg and placebo. The antinatriuretic response and the urinary dopamine response to ANGII did not differ within or between the two groups on each study day. No correlation was observed between the decrements in urinary sodium excretion and urinary dopamine output during ANGII infusion in either group. The effect of insulin on urinary dopamine excretion was studied separately in seven non-diabetic subjects; sodium and potassium retention occurred during a hyperinsulinaemic euglycaemic clamp, but urinary dopamine did not change. The data suggest that the relationship between urinary sodium excretion and tubular dopamine synthesis remains normal in early type 1 diabetes mellitus both at baseline and during the antinatriuresis induced by angiotensin II. The cause of the reduction in urinary dopamine during ANGII infusion is unclear, but is probably not mediated directly by changes in proximal tubular sodium transport.

Interaction of hypoxia and hypothermia on dorsal column conduction in adult rat spinal cord in vitro

Trauma reduces both action potential amplitudes and conduction velocities, as well as the ability of axons to follow high-frequency stimulation, in spinal cord dorsal columns. Since white matter blood flow falls after spinal cord injury, hypoxia may play a role in post-traumatic axonal dysfunction. We examined the effects of hypoxia on action potential conduction in isolated adult rat dorsal columns under normothermic (37 degrees C) and hypothermic (25 degrees C) conditions. After stabilization in oxygenated Ringer's solution (95% O2 and 5% CO2), the isolated dorsal columns were superfused with hypoxic Ringer's solution (95% N2 and 5% CO2) for 120 min, followed by 90 min of reoxygenation. At 37 degrees C, hypoxia markedly depressed response amplitudes to 25 +/- 9% (mean +/- SEM, n = 7) of prehypoxic levels but paradoxically increased population conduction velocity to 133 +/- 6%. Reoxygenation restored response amplitudes to 57 +/- 11% and population conduction velocities returned to prehypoxic levels. At 25 degrees C, the dorsal columns were significantly less sensitive to hypoxia. Response amplitudes fell to 50 +/- 6% (n = 7) after hypoxia and recovered to 77 +/- 6% after reoxygenation. Normothermic dorsal columns responded to 500-Hz stimuli with minimal amplitude changes before (-9 +/- 3%, n = 7) and after hypoxia (-13 +/- 2%). In hypothermic preparations, 500-Hz stimulation depressed response amplitudes before (-40 +/- 8%, n = 7) and after hypoxia (-56 +/- 8%); they were not significantly different from each other.(ABSTRACT TRUNCATED AT 250 WORDS)

Distinct promoters direct neuronal and nonneuronal expression of rat aromatic L-amino acid decarboxylase

Aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28) catalyzes the decarboxylation of L-dopa to dopamine in catecholamine cells and 5-hydroxytryptophan to serotonin in serotonin-producing neurons. This enzyme is also expressed in relatively large quantities in nonneuronal tissues such as liver and kidney, where its function is unknown. Neuronal and nonneuronal tissues express AADC mRNAs with distinct 5' untranslated regions. To understand how this is accomplished at the genomic level, we have isolated rat genomic DNA encoding AADC. The organization of the AADC gene suggests that there are two separate promoters specific for the transcription of neuronal and nonneuronal forms of the AADC message. A small exon containing 68 bases of the neuronal-specific 5' end is located approximately 9.5 kilobases upstream of the translation start site, which is contained in the third exon. Approximately 7 kilobases upstream from the neuron-specific promoter is another small exon containing 71 bases of the 5' end of the nonneuronal AADC message. These data suggest that transcription initiating at distinct promoters, followed by alternative splicing, is responsible for the expression of the neuronal and nonneuronal forms of the AADC message.

Terrestrial Carbon and Nitrogen Isotopic Ratios from Cretaceous-Tertiary Boundary Nanodiamonds

One hypothesis for the origin of the nanometer-size diamonds found at the Cretaceous-Tertiary (K-T) boundary is that they are relict interstellar diamond grains carried by a postulated asteroid. The (13)C/(12)C and (15)N/(14)N ratios of the diamonds from two sites in North America, however, show that the diamonds are two component mixtures differing in carbon and nitrogen isotopic composition and nitrogen abundance. Samples from a site from Italy show no evidence for either diamond component. All the isotopic signatures obtained from the K-T boundary are material well distinguished from known meteoritic diamonds, particularly the fine-grain interstellar diamonds that are abundant in primitive chondrites. The K-T diamonds were most likely produced during the impact of the asteroid with Earth or in a plasma resulting from the associated fireball.

Topical Application of Ice-Nucleating-Active Bacteria Decreases Insect Cold Tolerance

The majority of overwintering insects avoid lethal freezing by lowering the temperature at which ice spontaneously nucleates within their body fluids. We examined the effect of ice-nucleating-active bacteria on the cold-hardiness of the lady beetle, Hippodamia convergens , a freeze-intolerant species that overwinters by supercooling to ca. −16°C. Topical application of the ice-nucleating-active bacteria Pseudomonas syringae increased the supercooling point to temperatures as high as −3°C. This decrease in cold tolerance was maintained for at least 3 days after treatment. Various treatment doses (10 8 , 10 6 , and 10 4 bacteria per ml) and modes of action (bacterial ingestion and topical application) were also compared. At the highest concentration of topically applied P. syringae , 50% of the beetles froze between −2 and −4°C. After topical application at the lowest concentration, 50% of the individuals froze by −11°C. In contrast, beetles fed bacteria at this concentration did not begin to freeze until −10°C, and 50% were frozen only at temperatures of −13°C or less. In addition to reducing the supercooling capacity in H. convergens , ice-nucleating-active bacteria also significantly reduced the cold-hardiness of four additional insects. These data demonstrate that ice-nucleating-active bacteria can be used to elevate the supercooling point and thereby decrease insect cold tolerance. The results of this study support the proposition that ice-nucleating-active bacteria may be used as a biological insecticide for the control of insect pests during the winter.

Lithium pretreatment affects renal and systemic responses to angiotensin II infusion in normal man

1. Renal and systemic responses to infusion of angiotensin II (1.25 and 2.5 ng min-1 kg-1 body weight) were examined in ten normal males 12 h after single doses of 750 mg of lithium carbonate, 250 mg of lithium carbonate (n = 6) or placebo. 2. Baseline mean arterial pressure [mean (SEM)] was higher after 750 mg of lithium [93.1 (1.7) versus 89.5 (1.9 mmHg, P = 0.014], and the subsequent rise in blood pressure during angiotensin II infusion was lower [8.2 (1.8) versus 12.2 (2.4) mmHg, P less than 0.02]. 3. Lithium at a dose of 750 mg increased overnight urinary sodium excretion before the study. The fall in fractional sodium excretion during angiotensin II infusion was reduced after pretreatment with 750 mg of lithium [750 mg of lithium, 2.73 (0.24) to 1.34 (0.08)%; placebo, 2.69 (0.26) to 1.01 (0.11)%; P = 0.02]. The increases in effective filtration fraction [750 mg of lithium, 5.4 (1.0)%; placebo, 8.6 (0.7)%; P less than 0.05] and total effective renal vascular resistance [750 mg of lithium, 3700 (390) dyn s cm-5; placebo 5100 (460) dyn s cm-5; P = 0.03] during angiotensin II infusion were also attenuated after 750 mg of lithium. Responses after 250 mg of lithium did not differ from those after placebo. 4. The fall in plasma renin activity and the increase in plasma aldosterone concentration during angiotensin II infusion were similar on each study day. 5. Renal responses to exogenous angiotensin II are altered after pretreatment with a 750 mg dose of lithium in normal man. This dose of lithium is not an inert marker of sodium handling.

A New Type of Meteoritic Diamond in the Enstatite Chondrite Abee

Diamonds with delta(13)C values of -2 per mil and less than 50 parts per million (by mass) nitrogen have been isolated from the Abee enstatite chondrite by the same procedure used for concentrating Cdelta, the putative interstellar diamond found ubiquitously in primitive meteorites and characterized by delta(13)C values of -32 to -38 per mil, nitrogen concentrations of 2,000 to 12,500 parts per million, and delta(15)N values of -340 per mil. Because the Abee diamonds have typical solar system isotopic compositions for carbon, nitrogen, and xenon, they are presumably nebular in origin rather than presolar. Their discovery in an unshocked meteorite eliminates the possibility of origins normally invoked to account for diamonds in ureilites and iron meteorites and suggests a low-pressure synthesis. The diamond crystals are approximately 100 nanometers in size, are of an unusual lath shape, and represent approximately 100 parts per million of Abee by mass.

Isolation and characterization of nuclear proteins that bind to T cell receptor V beta decamer motif

TCR V beta promoter contains a highly conserved decamer homologous to cAMP response element (CRE). Recent studies have identified this CRE decamer as the dominant transcription-activating element within the TCR V beta promoter. We have isolated cDNA clones, TCR-ATF1 and TCR-ATF2, encoding DNA-binding proteins that recognize this CRE motif. The nucleotide sequence of TCR-ATF1 has not previously been reported, whereas that of TCR-ATF2 was homologous to CRE-BP1, ATF-2, and mXBP. Both TCR-ATF1 and TCR-ATF2 shared a conserved leucine zipper and DNA binding motif with other CRE-binding proteins. TCR-ATF1 and TCR-ATF2 were expressed in all cell lines examined and in mouse embryos as early as 12.5 days. Despite binding to the same CRE motif, TCR-ATF1 and TCR-ATF2 were different from CREB in the fine nucleotide specificity. TCR-ATF bound methylated CRE and CRE mutant M4 (4C----G) that were not recognized by CREB. Additionally, TCR-ATF1 weakly recognized two other single nucleotide mutants of V beta-CRE that were not bound by TCR-ATF2 and CREB. We have further demonstrated that TCR beta-chain expression was immediately activated by cAMP. Such induction is likely mediated through V beta-CRE sequence, because the inclusion of V beta-CRE in a vector with minimum promoter (pBLCAT2) conferred the cAMP inducibility of CAT activity.

Isolation and characterization of nuclear proteins that bind to T cell receptor V beta decamer motif

TCR V beta promoter contains a highly conserved decamer homologous to cAMP response element (CRE). Recent studies have identified this CRE decamer as the dominant transcription-activating element within the TCR V beta promoter. We have isolated cDNA clones, TCR-ATF1 and TCR-ATF2, encoding DNA-binding proteins that recognize this CRE motif. The nucleotide sequence of TCR-ATF1 has not previously been reported, whereas that of TCR-ATF2 was homologous to CRE-BP1, ATF-2, and mXBP. Both TCR-ATF1 and TCR-ATF2 shared a conserved leucine zipper and DNA binding motif with other CRE-binding proteins. TCR-ATF1 and TCR-ATF2 were expressed in all cell lines examined and in mouse embryos as early as 12.5 days. Despite binding to the same CRE motif, TCR-ATF1 and TCR-ATF2 were different from CREB in the fine nucleotide specificity. TCR-ATF bound methylated CRE and CRE mutant M4 (4C----G) that were not recognized by CREB. Additionally, TCR-ATF1 weakly recognized two other single nucleotide mutants of V beta-CRE that were not bound by TCR-ATF2 and CREB. We have further demonstrated that TCR beta-chain expression was immediately activated by cAMP. Such induction is likely mediated through V beta-CRE sequence, because the inclusion of V beta-CRE in a vector with minimum promoter (pBLCAT2) conferred the cAMP inducibility of CAT activity.

Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers

1. The pharmacokinetics of gludopa in healthy volunteers were studied at two doses, 250 micrograms kg-1 and 100 micrograms kg-1, after rapid intravenous bolus injection. 2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively. Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1. 3. Urinary excretion of dopamine rose sharply after injection of gludopa at both doses, peaking at 30 min. At this time, amounts were over 215 and 60 times baseline values at the higher and lower dose of gludopa, respectively. Urinary dopamine rose in parallel with urinary levodopa excretion, supporting the view that levodopa is the precursor of urinary dopamine. 4. Less than 1% of the injected dose of gludopa was excreted unchanged in the urine. 5. These findings suggest that, in man, gludopa is an efficient pro-drug for dopamine. Gludopa may find therapeutic use in conditions where the beneficial renal effects of dopamine may be indicated.

A single dose study of the effects of fenoldopam and enalapril in mild hypertension

To clarify the contribution made by the renin-angiotensin system activation to the short lived hypotensive response to fenoldopam, the haemodynamic effects of a combination of fenoldopam (100 mg) and enalapril (5 mg) were compared with fenoldopam alone, enalapril alone and placebo in a balanced, randomised, double blind, single dose study in eight hypertensive patients. Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia. Enalapril caused a more gradual fall in blood pressure (onset 2 h) without a reflex tachycardia. The combination of drugs produced greater reductions in blood pressure sustained for a longer period than fenoldopam alone and with a more rapid onset than enalapril alone. In combination the hypotensive effects of fenoldopam and enalapril were clearly additive and not synergistic. Activation of the renin-angiotensin system does not antagonise significantly the hypotensive effect of fenoldopam.

Oral carbidopa has no effect on the renal response to angiotensin II in normal man

1. The effect of inhibition of intrarenal dopamine synthesis by carbidopa on the renal response to angiotensin II infusion was studied in six healthy salt-loaded volunteers. 2. Subjects received an infusion of angiotensin II at two doses (0.5 and 1.0 ng min-1 kg-1) on two occasions. Before one study they took a single dose of carbidopa (100 mg) by mouth. 3. The plasma concentrations of angiotensin II produced by the infusion were similar on both study days. Angiotensin II infusion reduced urinary dopamine excretion on the control day. Urinary dopamine excretion was undetectable at all times after carbidopa, but carbidopa did not change the basal excretion rate of sodium. Despite inhibition of renal dopamine synthesis, the reductions in both absolute and fractional sodium excretion during the angiotensin II infusion were not different from those seen in the control study. 4. The reductions in glomerular filtration rate and effective renal plasma flow which occurred during angiotensin II infusion were not modified by pretreatment with carbidopa. 5. The renal response to angiotensin II is not modulated either wholly or in part by endogenous intrarenal dopamine levels. The fall in urinary dopamine excretion which occurs during angiotensin II infusion is consistent with a modulatory role for tubular reabsorptive capacity in the regulation of proximal tubular dopamine synthesis.

Five years' experience with gamma-L-glutamyl-L-dopa: a relatively renally specific dopaminergic prodrug in man

1. Over the last 5 years we have given intravenous gludopa in man and established its effects on the kidney. 2. At doses of 12.5 to 100 micrograms kg-1 min-1 it is natriuretic and also tends to increase renal blood flow and glomerular filtration. Despite the natriuresis, plasma renin activity is depressed and this effect is blocked by domperidone. The receptors for the tubular natriuretic effect are blocked by d-sulpiride. 3. Four-hour infusions in man do not lower blood pressure; 10-h infusions lower blood pressure and increase pulse rate. 4. The oral bioavailability of gludopa is only 1 to 2% and this rules out the dipeptide as an effective dopaminergic prodrug.

The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure

1. The pharmacokinetics of gamma-glutamyl-L-dopa (gludopa) and its metabolite, L-dopa, have been studied in normal rats at three dose levels of gludopa: 2 mg kg-1, 5 mg kg-1 and 7.5 mg kg-1. The extent of metabolism in normal rats, and the pharmacokinetics in anephric rats and rats with glycerol-induced acute renal failure (ARF) were also studied at a gludopa dose of 2 mg kg-1. 2. Gludopa was extensively metabolised to L-dopa with only about 10% of an injected dose being excreted unchanged. Normal rats had a rapid gludopa clearance of 50.9 +/- 9.6 ml min-1 kg-1 and elimination rate constant of 2.99 +/- 0.27 h-1. The mean residence time and half-life were 20.9 +/- 1.4 and 14.4 +/- 1.0 min, respectively. The apparent volume of distribution at steady state was 1.05 +/- 0.18 l kg-1. 3. No statistically significant differences were found in the main pharmacokinetic parameters between ARF and controls for either gludopa or its metabolite L-dopa. 4. In anephric rats and controls the kidneys were found to contribute about 68.5% and 67.2% to the elimination of gludopa and the metabolite L-dopa, respectively. 5. These results confirm that gludopa is an efficient pro-drug for L-dopa, and that the kidneys are the major site of gludopa metabolism. It seems likely that the renal specificity of gludopa persists in ARF.

Effect of cardiac tamponade on atrial natriuretic peptide concentrations: influence of stretch and pressure

1. In order to study the role of atrial pressure and atrial stretch on the release of atrial natriuretic peptide we have measured plasma atrial natriuretic peptide concentration, urine output and haemodynamic variables in eight patients during and 30 min after the relief of cardiac tamponade. This condition is characterized by high atrial pressure with little or no atrial stretch. 2. Relief of tamponade was associated with a rise in urine output (53 +/- 27.9 to 101 +/- 24.5 ml/h, mean +/- SEM; P = 0.09), systolic blood pressure (95 +/- 9.6 to 126 +/- 7.0 mmHg, P less than 0.0001), and plasma atrial natriuretic peptide concentration (369.5 +/- 70.9 to 490.3 +/- 94.7 pg/ml, P less than 0.05) despite a large fall in right atrial pressure (18.6 +/- 1.6 to 9.5 +/- 1.3 mmHg, P less than 0.001). 3. These results suggest, therefore, that an increase in atrial stretch, rather than in atrial pressure, stimulates the release of atrial natriuretic peptide.

Effects of felodipine on atrial natriuretic peptide in hypertensive non-insulin dependent diabetes mellitus

Eighteen patients with non-insulin dependent diabetes mellitus and hypertension were treated during two 4 week periods with the calcium antagonist felodipine or placebo in a double-blind, randomised, cross-over study. Mean systemic blood pressure was significantly lower on felodipine, without producing a deleterious effect on diabetic control. Felodipine was associated with an increment in plasma renin concentration but plasma aldosterone and the renal outputs of sodium and dopamine were similar on both treatments. Plasma atrial natriuretic peptide levels were significantly reduced following felodipine treatment.